Custopharm Revenue and Competitors

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Custopharm's estimated annual revenue is currently $5.4M per year.(i)
  • Custopharm's estimated revenue per employee is $201,000

Employee Data

  • Custopharm has 27 Employees.(i)
  • Custopharm grew their employee count by -40% last year.

Custopharm's People

NameTitleEmail/Phone
1
Snr. Director Commercial Operations/Supply Chain/Project ManagementReveal Email/Phone
2
Director Technology Transfer and ManufacturingReveal Email/Phone
3
Sr. Manager, Quality ControlReveal Email/Phone
4
Quality Assurance ManagerReveal Email/Phone
5
Sr. Associate, Regulatory AffairsReveal Email/Phone
6
method development chemistReveal Email/Phone
7
Principal ScientistReveal Email/Phone
8
Scientist, Analytical DevelopmentReveal Email/Phone
9
Analytical Development ScientistReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$84.8M42224%N/AN/A
#2
$0.4M20%N/AN/A
#3
$32M1593%N/AN/A
#4
$35M1213%$62.5MN/A
#5
$30.2M15018%N/AN/A
#6
$135.3M6730%N/AN/A
#7
$110.3M549N/AN/AN/A
#8
$60.1M299-4%N/AN/A
#9
$554.8M17252%N/AN/A
#10
$10.5M524%N/AN/A
Add Company

What Is Custopharm?

Founded in 2005, Custopharm has steadily grown to develop more than 30 products and serve more than 100 organizations across the pharmaceutical industry. In 2015 we partnered with Water Street Healthcare Partners, a strategic investor with extensive pharmaceutical expertise, to accelerate Custopharm's growth. Since then, we have been working towards becoming a U.S. leader in generic injectable drugs while striving to make therapies more accessible through our development portfolio of high barrier products. The Company is presently in an early commercial stage, with aggressive growth anticipated. Leucadia Pharmaceuticals was established in 2015 as the commercial arm of Custopharm, Inc., and is associated with Water Street Healthcare Partners.

keywords:N/A

N/A

Total Funding

27

Number of Employees

$5.4M

Revenue (est)

-40%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Custopharm News

2022-04-19 - Hikma acquires US company Custopharm for $425m

Hikma Pharmaceuticals has acquired US-based generic sterile injectables company Custopharm from Water Street Healthcare Partners in a deal...

2022-04-17 - Water Street Completes Sale of Custopharm

Working with the company's leadership team, Water Street transformed Custopharm into a leading franchise offering a portfolio of differentiated...

2022-04-17 - U.S. FTC approves Hikma deal for Custopharm with conditions

WASHINGTON, April 19 (Reuters) - Generic drug maker Hikma Pharmaceuticals (HIK.L) has won U.S. antitrust approval to buy Custopharm,...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
N/A2713%N/A
#2
N/A27-10%N/A
#3
$2.7M270%N/A
#4
$3.3M274%N/A
#5
$2.7M27N/AN/A